Form 10-Q bluebird bio, Inc. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Goldman Sachs Downgrades bluebird bio (BLUE) to Sell
November 8, 2021 7:38 AM ESTGoldman Sachs analyst Salveen Richter downgraded bluebird bio (NASDAQ: BLUE) from Neutral to Sell with a price target of $10.00 (from $23.00).
The analyst comments "We downgrade BLUE to Sell from Neutral and lower our 12-month PT to $10 from $23. Post the separation of the severe genetic disease (SGD; BLUE) and oncology businesses (2seventy bio; TSVT), BLUE is focused on developing and... More
Morgan Stanley Downgrades bluebird bio (BLUE) to Underweight, 'commercialization will remain challenging'
November 8, 2021 5:11 AM ESTMorgan Stanley analyst Matthew Harrison downgraded bluebird bio (NASDAQ: BLUE) from Equalweight to Underweight with a price target of $11.00 (from $19.00).
The analyst comments "Bluebird has developed a robust portfolio of genetherapies where we expect approval in 2022/2023. However, we believe the ultimate market for... More
